Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(9):670; doi:10.1093/jnci/93.9.670
© 2001 by Oxford University Press
This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 9, 670, May 2, 2001
© 2001 Oxford University Press

NEWS

Studies Document Early Success of STI-571

Results of a dose-escalation study and a phase 1 study of a compound called STI-571 indicate that the drug shows substantial activity against chronic myeloid leukemia and a specific subtype of acute lymphoblastic leukemia. The two reports were published April 5 in the New England Journal of Medicine.

STI-571 (Glivec, Novartis Pharmaceuticals) is a tyrosine kinase inhibitor that targets the fusion protein BCR-ABL, which is produced by the Philadelphia chromosome and is present in all cases of CML and in about 5% of all ALL cases.

A related editorial noted that the two reports "must be accepted as final proof that the BCR-ABL oncoprotein is the unique cause of chronic-phase CML."

(For a history of the development of STI-571, see News, Jan. 5, 2000, p. 6–8.)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?